On January 5, 2026, Japanese pharmaceutical firm Daiichi Sankyo unveiled a major investment plan of approximately $1.9 billion (300 billion Yen) to strengthen its oncology manufacturing infrastructure across Japan, the U.S., Germany, and China.
Strategic diversification and risk mitigation This initiative is a core part of the company’s strategy to bolster the production of its antibody-drug conjugate (ADC) portfolio, notably the breast cancer therapy Enhertu. By decentralizing its manufacturing footprint, the company aims to:
-
Stabilize supply chains: Ensure consistent drug delivery regardless of regional disruptions.
-
Mitigate geopolitical risks: Protect operations against potential changes in international tariffs or fluctuating regulatory landscapes.
Regional investment breakdown
-
Germany: The largest allocation of $894 million will enhance production sites in Munich for Enhertu and other key assets.
-
Japan: $491.7 million is designated for the expansion of an existing facility in Hiratsuka.
-
United States: $357.8 million will be invested in the Ohio plant, with construction of additional facilities expected to conclude by late 2027.
-
China: $153 million is earmarked for a new manufacturing site in Shanghai, scheduled for completion by 2030 to serve the local market.
This investment underscores Daiichi Sankyo’s commitment to scaling its ADC technology globally, addressing the unmet medical needs of patients with HER2-directed cancers and other solid tumors worldwide.
Source: https://www.contractpharma.com/breaking-news/daiichi-plans-to-invest-1-9b-in-production-facilities/